PropThink: As ACAD Rises into Pimavanserin Data, ATM Use May Continue

PropThink: As ACAD Rises into Pimavanserin Data, ATM Use May Continue

[ACN Newswire] – By Jake KingAcadia Pharmaceuticals (NASDAQ:ACAD) announced its 3Q financial results Monday, reiterating the expectation for top-line pimavanserin data by the end of the month and reporting the first use … more

View todays social media effects on ACAD

View the latest stocks trending across Twitter. Click to view dashboard

Share this post